Italy. WHO has recommended laboratory tests for any suspected cases alongside quarantining suspects, applying social distancing and frequent handwashing to contain the spread of 2019-nCoV In conclusion, though there are several promising studies with regard to the mechanism of action and activity of protease inhibitors against SARS-CoVs, there is no sufficient in vitro and in vivo studies against SARS-CoV-2 to confidently use them for COVID-19. They are being used in adhoc and compassionate manner based on case reports and previous experiences because of the absence of officially approved drug for this life threatening condition. Even if it could be taken as a bench mark, the recently published trial report is not sufficient and too early to conclude the poor clinical utility of Lopinavir/ritonavir without conducting multi-centered, randomized, blinded and well-established placebo controlled clinical trials.
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